The KEYNOTE B36 study is intended for patients who have been diagnosed with, but have not yet been treated for, advanced or metastatic intrathoracic non-small cell lung cancer (NSCLC). This clinical study is evaluating the safety and efficacy of Tumor Treating Fields (TTFields) delivered by the NovoTTF-200T device concomitant with a standard immunotherapy agent, pembrolizumab, for first line treatment of patients with NSCLC.

All patients enrolled in the study will receive TTFields treatment, together with pembrolizumab [The KEYNOTE B36 study].

Novocure GmbH, the study sponsor, maintains this website to help patients get basic information about the study.

If you want to take part in the KEYNOTE B36 study, please contact one of the participating centers [KEYNOTE B36 CENTERS] as soon as possible.

For patients who have recently been diagnosed with progression of non-small cell lung cancer (NSCLC) during or after platinum-based therapy, please see the LUNAR Trial.